Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

A2 Bio­ther­a­peu­tics has raised $80 mil­lion to run three ex­per­i­men­tal CAR-T pro­grams for sol­id tu­mor can­cers. The ...

Biopharma leaders head to San Francisco's JP Morgan Healthcare Conference amid hopes for M&A deals after slow 2024, which saw ...

Sutro scale-up, Pharma mergers, FDA warnings to Indian firms, new Egypt facility, and UPS acquires Frigo-Trans ...

Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie ...

A Dutch biotech cre­at­ing nasal sprays to pro­tect against the flu and coro­n­avirus has raised an ad­di­tion­al $70 ...

Tenpoint Therapeutics’ presbyopia drug showed “significant improvements” in near vision and reading speed in a Phase 3 trial. The biotech said the results keep it on track for an FDA filing in the ...

Novo Holdings co-leads €32M Series A for Coave Therapeutics, which is developing gene therapies with its ALIGATER technology.

H1 acquires Ribbon Health to expand doctor-patient connections. Ribbon serves about 25M patients yearly; H1 aims to reach ...

Baby with genetic OTC deficiency shows promising response to iECURE's first-in-kind gene therapy, potentially avoiding liver ...

Transcarent acquires Accolade for $621M in cash deal led by CEO Glen Tullman, combining health navigation platforms.

French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 ...